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Abstract
Background: Personalized molecular radiotherapy based on theragnostics requires
accurate quantification of the amount of radiopharmaceutical activity administered
to patients both in diagnostic and therapeutic applications. This international multi-
center study aims to investigate the clinical measurement accuracy of radionuclide
calibrators for 7 radionuclides used in theragnostics: 99mTc, 111In, 123I, 124I, 131I, 177Lu,
and 90Y.
Methods: In total, 32 radionuclide calibrators from 8 hospitals located in the
Netherlands, Belgium, and Germany were tested. For each radionuclide, a set of four
samples comprising two clinical containers (10-mL glass vial and 3-mL syringe) with
two filling volumes were measured. The reference value of each sample was
determined by two certified radioactivity calibration centers (SCK CEN and JRC) using
two secondary standard ionization chambers. The deviation in measured activity with
respect to the reference value was determined for each radionuclide and each
measurement geometry. In addition, the combined systematic deviation of activity
measurements in a theragnostic setting was evaluated for 5 clinically relevant
theragnostic pairs: 131I/123I, 131I/124I, 177Lu/111In, 90Y/99mTc, and 90Y/111In.
Results: For 99mTc, 131I, and 177Lu, a small minority of measurements were not within
± 5% range from the reference activity (percentage of measurements not within
range: 99mTc, 6%; 131I, 14%; 177Lu, 24%) and almost none were outside ± 10% range.
However, for 111In, 123I, 124I, and 90Y, more than half of all measurements were not
accurate within ± 5% range (111In, 51%; 123I, 83%; 124I, 63%; 90Y, 61%) and not all
were within ± 10% margin (111In, 22%; 123I, 35%; 124I, 15%; 90Y, 25%). A large
variability in measurement accuracy was observed between radionuclide calibrator
systems, type of sample container (vial vs syringe), and source-geometry calibration/
correction settings used. Consequently, we observed large combined deviations
(percentage deviation > ± 10%) for the investigated theragnostic pairs, in particular
for 90Y/111In, 131I/123I, and 90Y/99mTc.
(Continued on next page)
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Conclusions: Our study shows that substantial over- or underestimation of
therapeutic patient doses is likely to occur in a theragnostic setting due to errors in
the assessment of radioactivity with radionuclide calibrators. These findings underline
the importance of thorough validation of radionuclide calibrator systems for each
clinically relevant radionuclide and sample geometry.
Keywords: Activity measurement, Radionuclide calibrator, Accuracy, Theragnostics
Introduction
In the last decades, the application of personalized molecular radiotherapy using
theragnostics has gained a lot of interest in nuclear medicine [1, 2]. Theragnostic ap-
proaches aim to optimize molecular radiotherapy for individual patients using pre-
therapeutic diagnostic imaging. In particular, assessment of the therapeutic absorbed
dose to malignant tissue and to organs at risk based on these images facilitates a per-
sonalized therapeutic activity approach. These approaches require accurate quantifica-
tion of the activity administered to patients both in diagnostic and therapeutic
applications. Accurate activity calibration of radionuclide imaging equipment such as
SPECT and PET cameras is also essential in theragnostics, to enable an accurate esti-
mation of radiopharmaceutical uptake in patient tissues.
In practice, radionuclide activity calibrators are used to measure the radiopharmaceu-
tical activity to be administered to patients and are often the reference instrument for
calibrating SPECT and PET systems. Radionuclide calibrators are typically provided
with factory-set calibration factors for a variety of clinically relevant radionuclides. Usu-
ally, the calibration factors are calculated from energy-dependent sensitivity curves, de-
termined experimentally on a dedicated reference device using well-calibrated traceable
sources in standard containers [3]. In-factory calibration of medical devices is usually
limited to a small subset of (long-lived) radionuclides to ensure proper response of each
device with respect to the reference device. However, due to manufacturing tolerances
in device specifications, variations in response among radionuclide calibrators of same
model can occur, particularly in the low photon-energy range, which is generally not
tested in the factory. Moreover, sample geometries used in clinical practice differ in
shape, size, material, and filling volume from the standard container geometries used
for activity calibrations. Since radionuclide calibrator measurements are sensitive to
changes in system and sample measurement geometry [4, 5], the validity of generic
factory-set calibration factors is not guaranteed for clinically used radionuclides and
sample geometries.
Therefore, several international guidelines recommend a thorough validation of
radionuclide calibrator accuracy for all clinically used radionuclides and sample geom-
etries during acceptance testing [6–8]. These guidelines typically recommend a meas-
urement accuracy of ± 5–10% for diagnostic and ± 5% for therapeutic radionuclides.
However, although practice varies widely across Europe, more often than not radio-
nuclide calibrators are clinically implemented without such validation due to a lack of
available certified activity standards of (short-lived) clinically used radionuclides, ex-
pertise, and time/costs required to perform this validation. In fact, a multi-center study
investigating the radionuclide calibrator measurement accuracy among 15 Belgian
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hospitals performed between 2013 and 2015 revealed that none of the participating
centers assessed the accuracy of clinically used radionuclides [9].
Several studies [9–15] have reported on the measurement accuracy of various individ-
ual diagnostic and therapeutic radionuclides, and demonstrated large measurement de-
viations (> ± 10%), particularly for 111In, 68Ga, 123I, and 90Y. However, no study has
reported on the combined error of radiopharmaceutical activity measurements with
radionuclide calibrators in the increasing application of personalized molecular radio-
therapy based on a theragnostic approach. Therefore, we performed an international
multi-center study on the clinical measurement accuracy of 32 radionuclide calibrators
(7 different types from 4 vendors) for a comprehensive set of theragnostic radionu-
clides: imaging tracers 99mTc, 111In, 123I, and 124I, and their therapeutic companions
90Y, 177Lu, and 131I. Additionally, the combined deviation of activity measurements in a
theragnostic setting was evaluated for 5 clinically relevant theragnostic pairs: 131I/123I
and 131I/124I, which are used mostly for treatment of thyroid disorders such as differen-
tiated thyroid cancer and hyperthyroidism; 177Lu/111In and 90Y/111In, used for peptide
receptor radionuclide therapy of neuroendocrine neoplasms and prostate cancer; and
90Y/99mTc, used in the treatment of liver tumors and metastases with 90Y microspheres
[1, 2, 16].
Methods
Stock solution preparation
The radionuclides were obtained from various suppliers: [99mTc]-NaTcO4, [
123I]-NaI,
and [131I]-NaI from GE Healthcare (Eindhoven, The Netherlands); [124I]-NaI from BV
Cyclotron VU (Amsterdam, The Netherlands); [177Lu]-LuCl3 from IDB Holland
(Baarle-Nassau, The Netherlands); and [111In]-InCl3 and [
90Y]-YCl3 from Curium (Pet-
ten, The Netherlands).
[177Lu]-LuCl3, [
111In]-InCl3, [
90Y]-YCl3, [
131I]-NaI, and [124I]-NaI stock solutions and
samples were prepared within 24 h of the first day of the intercomparison measure-
ments, which took place over three consecutive days. Due to their shorter half-life,
[99mTc]-NaTcO4 and [
123I]-NaI solutions were prepared at each measurement day. For
each radionuclide, a stock solution was prepared with approximately 10MBq mL−1 on
the first measurement day. Stock solutions were prepared using sterile water (Baxter,
The Netherlands) in a borosilicate glass container and immediately after preparation
dispensed into samples to avoid precipitations.
Evaluation of radionuclidic impurities
Each stock solution was checked for radionuclidic impurities by high-resolution
gamma-ray spectrometry using a high-purity germanium detector (GR1018; Mirion
Technologies, Georgia, USA) as described in the supplemental material. No short- or
long-lived radionuclidic impurities were found for 99mTc, 111In, 131I, and 90Y. For 123I
and 124I, trace amounts of 125I were observed with a maximum radionuclidic impurity
of 0.030% and 0.037%, respectively. For 177Lu, trace amounts of 177mLu were observed
with a maximum radionuclidic impurity of 0.017%. Minimum detectable activities of
potential impurities not detected (99Mo, 114mIn, 121Te, 88Y) and the effect of (potential)
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impurities on a radionuclide calibrator are reported in the supplemental material (Table
S1) [17].
Determination of reference activity
The reference (true) activity concentration of each stock solution was determined by
the Belgian Nuclear Research Centre (SCK CEN) (Mol, Belgium) in collaboration with
the Joint Research Centre (Geel, Belgium), which is specialized in primary and second-
ary standardization of radioactivity [18]. Reference activity measurements were
performed using two secondary standard ionization chambers: a Fidelis (Southern-Sci-
entific, Henfield, UK) and an ISOCAL-III (Vinten Instruments, UK). The latter is con-
sistent with radioactivity standards from the JRC [9]. Both chambers are of the same
design and use calibration factors traceable to the primary standards of activity of the
UK National Physical Laboratory (NPL).
From each stock solution, three 10-mL type 1+ Schott vials (SCHOTT AG Pharma-
ceutical Systems, Mainz, Germany) [19] were filled with 4 mL of solution (calibration
geometry specified for the Fidelis), and their activities were assayed in both reference
chambers. With the exception of 90Y, the reference activity of each Schott vial was de-
termined from the mean of the activities measured with both the Fidelis and the ISO-
CAL, and the gravimetrically determined mass of stock solution in the vial. All activity
measurements were corrected for background signal and for radioactive decay to a
common reference time using the half-life values published in the NuDat database ver-
sion 2.8 [20]. Additionally, before determination of the average value, the activity mea-
surements were corrected for linearity, radionuclide impurities (significant only for
(177mLu/)177Lu measurements), and deviations in response against the NPL master
chamber (see supplementary Table S2). For the latter correction, radionuclide- and
chamber-dependent correction factors were estimated from the NPL acceptance testing
data of each system (corrections < 1.1% for the gamma emitters and 14.5% for the 90Y
Fidelis measurements), as described in the supplementary data [21].
With the exception of 90Y, the Fidelis and ISOCAL systems agreed within ± 0.7% in
Schott vial activity measurements. For 90Y, however, a difference in response of ap-
proximately 10% was observed between both systems. On the basis of this discrepancy
and the lack of experimental data to correct the response of the ISOCAL against the
NPL master chamber for pure beta emitters, the reference activity concentration of the
90Y stock solution was derived from activity measurements with the Fidelis only. The
reference activity concentration of the radionuclide stock solution was then determined
as the mean of the activity concentrations from the three Schott vials. The expanded
uncertainty (95% confidence level) in the reference activity concentrations of the stock
solutions was 2.0% for 99mTc, 1.7% for 111In, 2.2% for 123I, 2.0% for 124I, 1.1% for 131I,
1.2% for 177Lu, and 6.9% for 90Y (see supplementary Table S3).
Sample preparation
From each stock solution, a set of four samples comprising two different clinical
containers each with two filling volumes were prepared: two 3-mL Luer-lock syringes
(Terumo Europe, Leuven, Belgium) filled with 1 mL and 3mL of solution, and two 11-
mL TechneVial glass vials (Curium, Petten, The Netherlands) filled with 1 mL and 10
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mL of solution. Each syringe was sealed with a combi-stopper (Braun, The
Netherlands). The content mass of each sample was verified gravimetrically, by weigh-
ing the sample before and after filling with an analytical balance (XS105DU/M;
Mettler-Toledo, Tiel, The Netherlands). The reference activity (Aref) of each sample
was calculated by multiplying the content mass with the stock solution reference activ-
ity concentration. As the uncertainty in sample mass measurements was negligible
compared to the uncertainty in radioactivity concentration, the relative uncertainty of
the sample reference activity (uref) was approximately equal to the relative uncertainty
of the stock solution activity concentration.
Due to transport logistics, for one hospital, separate sets of samples (a 3-mL syringe
filled with 3 mL and a TechneVial filled with 10 mL of stock solution) were prepared
for all radionuclides.
Clinical activity measurements
Sample measurements were performed on a total of 32 radionuclide calibrator systems
of 8 university hospitals located in the Netherlands, Belgium, and Germany. Of all sys-
tems, 4 were manufactured by Capintec Inc (Florham Park, USA), 11 by former MED
Nuklear-Medizintechnik (now Nuvia Instruments, Dresden, Germany), 1 by PTW-
Freiburg (Freiburg, Germany), and 16 by former Veenstra Instruments (now Comecer
Netherlands, Joure, The Netherlands) (see supplemental Table S4).
If applicable, measurements were performed using hospital-specific calibration
settings and sample geometry corrections. Otherwise, standard factory settings were
used (see supplementary Tables S5-S11). The standard (automatic) measurement
(averaging) time of the calibrator was used. Three activity readings (n = 3) were
taken sequentially, without moving the sample, at intervals of several seconds
(dependent on observed system response time). The calibrator reading was left to
settle (typically for about 15 to 30 s) before the first reading was taken. The range
of the sample activities at the moment of clinical measurements is indicated in
Table 1. Each measurement was corrected for background signal and radioactive
decay. For each measurement triplet, the average net activity (Ām) and standard de-
viation (SD) were calculated. The statistical measurement uncertainty (um) was esti-
mated at the 95% confidence level (coverage factor k = 4.30 for a t-distribution
with two (n − 1) degrees of freedom), as follows:
Table 1 Sample reference activities (minimum–maximum (25th percentile)) at the moment of
clinical activity measurements
Radionuclide Minimum Aref–maximum Aref (25th percentile) (MBq)
Syringe 1mL Syringe 3mL Vial 1 mL Vial 10mL
99mTc 3.9–18.5 (6.7) 10.3–44.3 (18.1) 4.3–18.0 (7.1) 34.1–147.8 (58.6)
111In 5.3–9.5 (5.7) 14.4–25.6 (15.4) 5.9–10.5 (6.3) 48.1–85.6 (51.4)
123I 6.7–17.6 (9.6) 17.6–47.5 (25.2) 7.8–19.9 (11.1) 60.7–161.6 (86.6)
124I 6.8–10.3 (7.1) 10.8–25.4 (17.4) 7.9–12.0 (8.3) 35.0–85.7 (58.6)
90Y 17.3–38.8 (18.7) 20.4–94.3 (45.2) 14.4–32.4 (15.6) 67.4–312.4 (149.7)
131I 10.8–13.4 (11.1) 20.4–31.5 (26.0) 13.1–16.2 (13.4) 66.8–105.7 (87.3)
177Lu 8.9–12.5 (9.2) 17.8–34.2 (25.2) 10.4–14.4 (10.7) 57.9–111.4 (82.0)
Saldarriaga Vargas et al. EJNMMI Physics            (2020) 7:69 Page 5 of 18
um ¼ k ∙SD
Am∙
ffiffiffi
n
p ð1Þ
Net activities were not corrected for the presence of radionuclidic impurities (if any).
Evaluation of performance
Individual radionuclides
The radionuclide calibrator measurement accuracy was determined as the percentage
deviation of the average measured activity Ām with respect to the sample reference ac-
tivity Aref.
For each radionuclide and sample geometry, the typical accuracy and reliability of ac-
tivity measurements were described in terms of the median and the inter-quartile range
(IQR) values of the measurement percentage deviations of all systems pooled together.
Similarly, these metrics were used to assess the manufacturer dependence of measure-
ment accuracy and inter-system variability. Sample geometry effects were evaluated by
comparing the measurement deviations of the syringe and vial samples with similar fill-
ing volume (syringe 1 mL vs vial 1 mL, syringe 3 mL vs vial 10 mL).
Theragnostic pairs
Finally, since patient tissue doses are proportional to the amount of therapeutic activity
administered and in a theragnostic approach the amount of therapeutic activity is based
on diagnostic imaging, the combined systematic percentage deviation (bias) that would
be associated to therapeutic doses (ED) was calculated for the theragnostic pairs
131I/123I, 131I/124I, 177Lu/111In, 90Y/99mTc, and 90Y/111In, as follows:
ED ¼
Am=Aref
 
therapy
Am=Aref
 
imaging
− 1
" #
∙100% ð2Þ
Results
Data analysis
In total, 32 radionuclide calibrator systems were investigated. If no calibration setting
was available for a specific radionuclide (see supplemental Tables S4-S10), that radio-
nuclide was not measured on that system. One system (E1) appeared defective as it
systematically underestimated the activity (typically by more than 10%) of all samples
(see Fig. 1). Therefore, this system was excluded from further analysis. This resulted in
a total of 745 activity measurement datasets for further analysis.
An overview of the intercomparison results is provided in Fig. 1 as box-whisker plots
of the percentage deviations from all analyzed radionuclide calibrator measurements.
Figures 2 and 3 show the individual percentage deviations grouped per manufacturer
(excluding defective/invalid measurements), for the diagnostic and therapeutic radionu-
clides, respectively. Table 2 indicates the percentage of activity measurements that
exceeded a given range of deviation from the reference activity.
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Diagnostic radionuclides
99mTc
For 99mTc, only 6% (7/110) of all measurements were not within ± 5% of the reference
value. No dataset showed deviations larger than ± 10%. For all sample configurations,
the median deviation was within 3.2% from the reference value and there was little
spread in measurement deviations (largest IQR 4%), indicating a good and reproducible
measurement accuracy for 99mTc.
With a median difference of less than ± 2% in measurement deviations between sy-
ringes and vials (IQR 3%), the dependency on container type was mostly small.
111In
A substantial amount of the 111In measurements did not meet the recommended ac-
curacy of ± 5% (51%; 53/104), nor the less strict limit of ± 10% (22%; 23/104). Although
the median deviation of all systems was within 3.5% from the reference value for all
sample types, the IQR ranged up to 12%.
Additionally, the measurement accuracy often depended on sample container, with a
median difference between syringes and vials of ± 8% (IQR 14%). Typically, this was
most pronounced for systems that did not incorporate any correction for measurement
geometry (i.e., Capintec systems, D3, E3, E4, G1–G3). However, even systems with
sample geometry calibration/correction settings were not always accurate within ± 5%
or ± 10% (Isomed F3–F6).
Fig. 1 Box-whisker plots and mean values of the percentage deviations of all activity measurements used
for analysis, for each radionuclide sample configuration tested (90Y whisker limits not shown: syringe 1 mL
423.9%, syringe 3 mL -383.6%). Additionally, the percentage deviations from defective measurements
excluded from the analysis and box-whisker plots are shown as data points
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Fig. 2 Percentage deviations of all the activity measurements used for analysis, for each system tested, for
the diagnostic radionuclides. a 99mTc, b 111In, c 123I, d 124I. Systems using sample geometry calibration/
correction factors are labeled with an asterisk (*)
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123I
The majority of the 123I measurements did not meet the recommended ± 5% accuracy
limit (83%; 88/106). Moreover, a substantial amount of measurements did not meet the
± 10% limit either (35%; 37/106). For all the samples, the median deviation of all sys-
tems was within 7.4% from the reference value, and the largest IQR was 30%. Further-
more, we observed a large dependence on sample type with a median difference
between syringes and vials of ± 17% (IQR 16%).
Typically, systems without sample geometry corrections tended to overestimate the
activity in syringes but underestimate the activity in vials, whereas the opposite trend
was observed for systems that did incorporate sample geometry corrections.
Fig. 3 Percentage deviations of all the activity measurements used for analysis, for each system tested, for
the therapeutic radionuclides. a 131I, b 177Lu, c 90Y (data not shown: D1 syringe 1 mL 158.2%, D1 syringe 3
mL 94.0%, H2 syringe 1 mL 423.9%, H2 syringe 3 mL 383.6%). Systems using sample geometry calibration/
correction factors are labeled with an asterisk (*)
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124I
A substantial amount of the 124I measurements did not meet the recommended ± 5%
(63%; 59/94) nor the less strict limit of ± 10% (15%; 14/94). For all the samples, the me-
dian deviation of all systems was within 4.9% from the reference value, and the largest
IQR was 16%. Additionally, with a median difference between syringes and vials of ±
10% (IQR 8%), 124I showed a substantial sensitivity to sample geometry. Syringe mea-
surements showed a rather small overestimation in measured activity (largest median
deviation of 4.8%) with a relatively small IQR (maximum 6%). For vials, however, the
accuracy typically depended on whether the system used sample-specific calibration/
correction settings (median deviation of all vial measurements of 9.1%) or not (− 6.3%).
Therapeutic radionuclides
131I
For 131I, 14% (16/111) and 3% (3/111) of all activity measurements were not within ±
5% and ± 10% of the reference values, respectively. For all the samples, the median de-
viation of all systems was within 1.1% from the reference value, and the largest IQR
was 7%. Furthermore, with a median difference of less than ± 2% between the devia-
tions of syringes and vials (IQR 3%), sample geometry effects were mostly small.
177Lu
A substantial amount of all 177Lu measurements did not meet the recommended ± 5%
(24%; 26/110) criterion. However, no dataset showed deviations exceeding the ± 10%
limit. For all the samples, the median deviation was within 3.7% from the reference
value. All IQR values were within 4%, indicating a fair to good reproducible measure-
ment accuracy. Moreover, with a median difference of approximately ± 1% between the
deviations of syringes and vials (IQR 2%), sample geometry effects were small.
Table 2 Percentage of activity measurements that exceed a given deviation from the reference
activity
Radionuclide Sample
type
Deviating measurements (%) No. of
measurement
datasets
No. of
systems
tested
± 5% ± 10%
99mTc Syringes 3.6 0.0 55 28
Vials 9.1 0.0 55 28
111In Syringes 61.5 25.0 52 26
Vials 40.4 19.2 52 26
123I Syringes 67.9 34.0 53 27
Vials 98.1 35.8 53 27
124I Syringes 36.2 12.8 47 25
Vials 89.4 17.0 47 25
90Y Syringes 74.5 27.3 55 29
Vials 47.3 23.6 55 29
131I Syringes 10.7 3.6 56 30
Vials 18.2 1.8 55 29
177Lu Syringes 18.2 0.0 55 29
Vials 29.1 0.0 55 29
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90Y
The majority of the 90Y measurements did not meet the recommended ± 5% accuracy
limit (61%; 67/110). Moreover, a substantial amount of measurements did not meet the
± 10% limit (26%; 28/110). We observed a large variability in measurement accuracy
depending on the system (type) and manufacturer.
Isomed systems, using specific calibration settings for each sample configuration,
often showed very large underestimation (> 30%) of the 90Y reference activity, most
pronounced for syringes, with IQR values up to 45%. Additionally, we found a large
variability in performance between systems of the same type using identical calibration
factors (e.g., A1 vs F1). Moreover, with a median difference between the deviations for
syringes and vials of ± 33% (IQR 30%), geometry effects were very large.
Instead, the other radionuclide systems typically performed better, particularly for
vials. For all sample configurations, the mean deviations were within 3.5%, and the lar-
gest IQR was 12%. With a median difference in measurement deviations between syrin-
ges and vials of ± 6% (IQR 8%), geometry effects were much smaller compared to the
Isomed systems.
Interestingly, two systems resulted in unexpectedly high deviations from the reference
activity: Isomed D1 (maximum deviation 158%) and Veenstra H2 (maximum deviation
424%).
Theragnostic pairs
Figure 4 shows the combined systematic percentage deviations for the theragnostic
pairs considered (131I/123I, 131I/124I, 177Lu/111In, 90Y/99mTc, 90Y/111In), when both radio-
nuclides are measured on the same device with the same sample geometry.
The combined deviations of the theragnostic pairs show substantial variability in
measurement accuracy between systems and manufacturers with a dependency on cali-
bration/correction setting and sample geometry. Generally speaking, roughly half of all
investigated theragnostic combinations would introduce a bias in the therapeutic dose
larger than ± 5%, and for one quarter of these combinations in a bias larger than ± 10%
(Table 3). This performance is even worse when activity measurements in different
containers are combined: of all administrations, two thirds would introduce a bias lar-
ger than ± 5% and one third larger than ± 10% (data not shown).
Discussion
Administering the correct amount of therapeutic activity to patients is of utmost im-
portance in personalized molecular radiotherapy. Typically, (inter)national guidelines
recommend stricter accuracy demands (± 5%) for therapeutic than for diagnostic radio-
nuclides (± 5–10%) [6–8]. However, in case of theragnostics, where the therapeutic ac-
tivity is optimized based on pre-therapeutic dosimetry/uptake calculations using
diagnostic imaging, accurate quantification of the diagnostic activity is of equal import-
ance as accurate therapeutic activity quantification. Therefore, to prevent introducing a
substantial error in the therapeutic doses delivered to patients, we advocate to apply
the ± 5% accuracy limit also for diagnostic radionuclides in a theragnostic setting.
In our study, we found one radionuclide calibrator (E1) that showed large deviations
(> 10% underestimations) for all radionuclides, therefore appearing to be
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Fig. 4 Percentage combined deviations for the theragnostic radionuclide pairs considered, when both
radionuclides are measured on the same device and using the same sample geometry. a 131I/123I, b 131I/124I,
c 177Lu/111In, d 90Y/111In, e 90Y/99mTc
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malfunctioning. This system was recently installed and was not yet (fully) validated nor
released for clinical use. These observations indicate that extensive validation of all
clinically used radionuclides is of vital importance.
Individual radionuclides
This intercomparison shows that radionuclide calibrator measurements of 99mTc,
still the workhorse of nuclear medicine, are (nearly) always correct, in agreement
with values reported in literature [9, 14]. The same cannot be said for the other
diagnostic radionuclides evaluated. For 111In, 123I, and 124I, measurement deviations
frequently exceeded the ± 5% and often even the ± 10% limits. This is in agree-
ment with values reported in literature for 111In and 123I [9, 10, 12]. To the best
of our knowledge, no multi-center data are available on the typical accuracy of 124I
clinical activity measurements. In particular, these radionuclides (111In, 123I, and
124I) show a large dependence on sample geometry (particularly sample container)
caused by self-absorption of the emitted low-energy X-rays within the sample itself.
Consequently, accurate activity measurement of these radionuclides requires spe-
cific calibration or correction factors for the sample geometry [22, 23]. When fac-
tory settings dedicated to specific sample configurations are available, they must be
experimentally verified prior to clinical use, as they might not be accurate for the
specific containers used locally. This was the case for many activity measurements
of 123I, 111In, and 124I. Alternatively, selective absorption of low-energy X-rays
using a copper/aluminum filter is an effective method to minimize the variability
in activity measurements caused by sample geometry [23, 24]. In this intercompari-
son, a copper filter was available for two systems, but appropriate calibration fac-
tors for measurements with filter had yet to be determined.
Regarding the therapeutic radionuclides, 177Lu measurements were almost always
within ± 5% from the reference activity, and never deviated by more than ± 10%, in
agreement with values previously reported for Capintec systems [13]. A tendency to
overestimate the reference activity values by typically a few percent was observed,
which might (partially) be attributed to the calibrators being sensitive to the presence
Table 3 Percentage of theragnostic activity measurements that exceed a given deviation from the
reference activities
Theragnostic
pair
Sample
type
Deviating measurements (%) No. of pairs of
measurement
datasets
No. of
systems
tested
± 5% ± 10% ± 20%
131I/123I Syringes 64.2 41.5 1.9 53 27
Vials 75.0 25.0 7.7 52 26
131I/124I Syringes 44.7 4.3 0.0 47 25
Vials 47.8 4.3 0.0 46 24
177Lu/111In Syringes 55.8 25.0 0.0 52 26
Vials 30.8 15.4 5.8 52 26
90Y/99mTc Syringes 67.9 32.1 26.4 53 27
Vials 52.8 20.8 13.2 53 27
90Y/111In Syringes 57.7 50.0 26.9 52 26
Vials 65.4 42.3 19.2 52 26
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of the 177mLu impurity. Our study presents new data for 177Lu, particularly on the
accuracy of medical calibrators from different suppliers, and using clinical sample
configurations. Similar as for 177Lu, the majority of calibrators were accurate for
measuring 131I albeit with a slightly higher deviation (sometimes > ± 5%, rarely >
± 10%). This is in agreement with values reported in literature [15]. In contrast,
for 90Y, some systems showed incorrect measurements to an unacceptable level:
the deviation ranged from a 72% underestimation to a 424% overestimation. In-
deed, in literature, large measurement errors up to ± 50% have been reported [13].
In particular, although all Isomed devices used factory-set corrections for sample
geometry, they were highly sensitive to the sample container and volume of solu-
tion and large measurement deviations were observed. Also, two systems (D1 and
H2) showed extremely high overestimations for the syringe measurements, but not
for the vials. Interestingly, this effect was not observed for other systems of the
same type and with the same (factory-set) calibration factors. Most likely, in these
two systems, high-energy beta radiation was able to reach the ionization chamber
in the syringe samples but not in the vial samples. Indeed, the radionuclide calibra-
tor response to high-energy beta particles is highly sensitive to even small varia-
tions in the material and design specifications of the measurement set-up [4]. This
clearly indicates the importance of extensive validation of each individual system
for each radionuclide and clinically used sample geometry.
Theragnostic applications
The present study sets the first reference on typical combined errors associated to clin-
ical radiopharmaceutical activity measurements in a theragnostic setting. Considering 5
clinically relevant theragnostic pairs (131I/123I, 131I/124I, 177Lu/111In, 90Y/99mTc,
90Y/111In), this intercomparison study showed that poor accuracy in radionuclide cali-
brator activity measurements of therapeutic and diagnostic radionuclides can introduce
a relatively large (> ± 10%) bias in the therapeutic doses delivered to patients in therag-
nostic applications. Such errors should be minimized as much as practically possible,
therefore the recommendation to apply a standard ± 5% accuracy limit to calibrator ac-
tivity measurements of both therapeutic and diagnostic radionuclides.
The best way to limit the error in the administration of activity is to ensure ac-
curate and reproducible activity measurements of both radionuclides involved in
the theragnostic application. This can be achieved by proper evaluation of the ac-
curacy of the measurement settings of the calibrators for the radionuclides and
sample configurations found in clinical practice, together with an assessment of
other sources of uncertainty in the activity measurements and proper maintenance
through a quality assurance program [6]. These procedures may lead to re-
calibration of the device or determination of appropriate correction factors, and
optimization of the source configurations (e.g., choice of container) or other meas-
urement settings or procedures used for activity measurements. After all, the error
in the assessment of patient administered activities is only one of the several
sources of uncertainty in the dosimetry process [25]. Minimizing its contribution
to the overall uncertainty is the best starting point towards patient treatment
optimization in molecular radiotherapy.
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Uncertainties in the clinical activity measurements of this study
As reported in detail by Gadd et al. [5], radioactivity measurements using radionuclide
calibrators are affected by different sources of uncertainty, including the accuracy of
calibration factors, sample geometry effects, photon-emitting radionuclide impurities,
background variability, system non-linear response, short-term response variability, re-
producibility of sample position, and influence of external shielding. These uncertainty
components are dependent on the specific measurement set-up (calibrator unit and its
accessories, shielding, local background field), the radionuclide, and/or the level of ac-
tivity (ionization current) being measured.
In this study, the clinical measurement accuracy of radionuclide calibrators was
tested for 7 radionuclides used in theragnostics, each in 4 sample configurations.
The effect of the sample type of container (syringe vs vial) was evaluated. As previ-
ously addressed, this effect was a significant source of variability in the activity mea-
surements of all the radionuclides, with the magnitude of the effect (median) being
large (> ± 5%) for 90Y, 123I, 111In, and 124I; mostly small (± 2%) for 131I and 99mTc; and
small (± 1%) for 177Lu.
The influence of the short-term response variability in the activity measurements was
reduced by taking the average of three consecutive activity readings. Although the
measurement statistical uncertainty um was within 0.7% for the large majority (> 75%)
of the activity datasets, which indicates a good short-term measurement reproducibility,
it is not negligible and in a clinical setting (where an average value is generally not esti-
mated) would cause a spread in the activity assessment.
The background reading was subtracted from all activity measurements. Yet, the un-
certainty due to background variability was not assessed. This uncertainty can have an
important bearing in the measurement of low activities and radionuclides with a low
response per unit activity, such as 90Y. In this study, the highest background-to-sample
reading ratios were obtained, as expected, with the vials with 1 mL (samples with low
activity), and were ≤ 3.7% for 90Y, 1.7% for 177Lu, and 0.9% for the other radionuclides.
For the vials filled with 10mL (samples with the highest activity), background fractions
were considerably lower (less or equal to 0.6% for 90Y and 0.2% for the other radionu-
clides). Assuming a high uncertainty of 10% in the background measurement, the po-
tential error introduced in the estimated net activities of the low-activity vial samples of
this study would be ≤ ± 0.38% (90Y), ± 0.17% (177Lu), and ± 0.09% (other radionuclides).
Although such potential error is not negligible for 90Y and 177Lu, it is much lower com-
pared to the measurement deviations observed in this intercomparison for the vial and
syringe samples with 1–3mL, suggesting that it is not the main cause of the spread in
90Y and 177Lu measurements of the samples with the lowest activities. For the other
samples and radionuclides, the potential error from the background uncertainty is
negligible.
All radionuclide solutions were checked for the presence of photon-emitting impur-
ities by high-resolution gamma spectrometry. Impurities were detected only in 123I
(125I), 124I (125I), and 177Lu (177mLu). From these impurities, only the 177mLu impurity
has a significant effect on activity measurements in a radionuclide calibrator (0.51%
overresponse for the Fidelis). Since the activities measured with the hospital calibrators
were not corrected for this effect, this remains a source of uncertainty in the 177Lu in-
tercomparison results.
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Information regarding other sources of uncertainty was not gathered from the partici-
pating hospitals. Yet, hospitals were encouraged to make a more detailed uncertainty
assessment for their activity measurements, since this is essential to evaluate the agree-
ment with the reference values and determine which corrective actions are needed to
improve the accuracy and reliability of their activity measurements. In general, that as-
sessment should be within the practical reach of hospitals, since most of the sources of
error mentioned above can be quantified by following a thorough quality control pro-
gram [5, 6, 8].
Study limitations
It should be noted that not all the calibrator systems tested were clinically used to
measure all the radionuclides considered in this study. Since hospitals may validate
a device only for the specific radionuclides used in their clinical practice, some
specific results of this study may not fully represent the local (hospital) measure-
ment capability.
Clinical activity measurements can bear additional uncertainties beyond those
accounted in this study. The amounts of activities administered to patients in nu-
clear medicine theragnostics are in the range of tens to several hundred megabec-
querels for imaging studies and a couple to several gigabecquerels for therapeutic
purposes, whereas in this study the sample activities were in the range of 4–162
MBq for diagnostic radionuclides and 9–312MBq for therapeutic radionuclides
(see values per radionuclide in Table 1). Linearity effects, which are typically in the
range of ± 1% to few percent [3, 5], become more important for the much broader
range of activities measured in clinical applications. Also, in clinical practice, thera-
peutic and diagnostic radionuclides are often not measured using the same (sam-
ple) measurement geometry. For instance, 90Y is often assayed using manufacturer-
supplied vials and/or acrylic shields. Indeed, the (combined) errors in theragnostic
activity measurements will depend on the specific measurement settings used for
each radionuclide. Moreover, the response of a radionuclide calibrator to 90Y also
depends on the physicochemical form of the 90Y compound [26]. In this study, 90Y
samples were prepared based on a 90Y chloride aqueous solution. Yet, in liver
radioembolization procedures, which represent the main clinical application of the
theragnostic pair 90Y/99mTc, 90Y is administered to patients in the form of suspen-
sions of resin/glass microspheres. Activity measurements of 90Y microspheres may
require the use of different calibration factors and present further challenges whose
associated errors might not be reflected in the overall measurement performance
obtained here using 90Y chloride.
Conclusion
This intercomparison showed that, while 99mTc, 131I, and 177Lu activity measure-
ments are mostly accurate, there is still significant room for improvement for
111In, 123I, 124I, and 90Y. For these radionuclides, the radionuclide calibrator re-
sponse is particularly sensitive to the sample and detector geometry. Consequently,
substantial over- or underdosing (> ± 10%) of therapeutic administrations is likely
to occur in a theragnostic setting. A key message from this intercomparison is that,
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prior to clinical release, radionuclide calibration factors and sample geometry cor-
rection factors should be verified for each radionuclide and sample configuration
used in practice. A unified international standard for testing and calibrating med-
ical radionuclide calibrators is pressingly needed to boost the implementation of
quantitative accuracy in nuclear medicine theragnostics.
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